Oslo (Norway), 8 January 2026 - PCI Biotech (OSE: PCIB). Reference is made to
the company's latest announcement dated 23(rd) October 2025. The external
evaluation of a new bioprocessing technology has been concluded, with no
prospects for further collaboration. As PCI Biotech's limited operations were
contingent upon sustained external interest, all R&D operations will now be
discontinued.
In recent months, various strategic alternatives have been explored, and this
process continues. The evaluation is made with careful consideration of the
company's circumstances, and includes a range of options, including, but not
limited to, a merger or a structured wind-up of the company.
The liquidity position of the PCI Biotech group remains critical, and there is
no assurance that additional financing can be secured. These material
uncertainties cast significant doubt on the PCI Biotech group's ability to
continue as a going concern.
Further information will be communicated as and when appropriate.
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, www.pcibiotech.com
Ronny Skuggedal, CEO
Email: rs@pcibiotech.no
Mobile: +47 9400 5757
Forward-looking statements
This announcement may contain forward-looking statements, which as such are not
historical facts, but are based upon various assumptions, many of which are
based, in turn, upon further assumptions. These assumptions are inherently
subject to significant known and unknown risks, uncertainties and other
important factors. Such risks, uncertainties, contingencies and other important
factors could cause actual events to differ materially from the expectations
expressed or implied in this announcement by such forward-looking statements.
PCI Biotech disclaims any obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or otherwise.
This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and subject to the disclosure requirements pursuant to
section 5-12 of the Norwegian Securities Trading Act. This stock exchange
announcement was published by Ronny Skuggedal, CEO at PCI Biotech Holding ASA,
on 8 January 2026 at 14:10 CET.